Takeda Canada said Health Canada has provided market authorization for FRUZAQLA, indicated for the treatment of adult patients with ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLAtm (fruquintinib capsules), indicated for the treatment of adult patients with ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for ...

When it comes to the bumper $62bn takeover of UK drugs group Shire by its larger Japanese rival Takeda Pharmaceutical (whose ...

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated ...

"Our top strategic objective for 2025 is the development of CX-2051, a wholly-owned, first-in-class PROBODY ADC being developed initially in advanced metastatic colorectal cancer (CRC). CX-2051 ...

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced updated ...

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda Quinta, 31 de Outubro de 2024 (2 meses atrás) • GlobeNewswire Inc.

With three internally-discovered medicines marketed in China, it is building on momentum around Fruzaqla, its first cancer drug that broke into developed markets like the US, Europe and Japan via ...

Recent advancements in treatment include the US FDA's approval of Takeda's FRUZAQLA in November 2023 for adults with metastatic colorectal cancer who had previously received specific chemotherapy ...